Company Overview
Vernalis is a UK-based biotechnology company with a marketed product, Frovatriptan, to treat migraine and a development pipeline focused on CNS disease and oncology. The company has five products in clinical development and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec and Serono. Vernalis is establishing a US commercial operation to co-promote frovatriptan alongside its North American licensing partner, Endo Pharmaceuticals, propelling the company towards its goal of becoming a sustainable, self-funding, R&D-driven biotechnology company.